# RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

> **NCT05154344** · — · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 182 (actual)

## Conditions studied

- MET Alterations
- Non Small Cell Lung Cancer
- METex14 Mutations

## Interventions

- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT05154344
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2023-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154344, "RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05154344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*